Decoy Cells Trick SARS-CoV-2, Reduce Cytokines In Vitro
Genetically engineered cells that overproduce ACE2, the receptor the novel coronavirus uses to enter cells, neutralize infection in vitro and mop up inflammatory cytokines in mice.
Decoy Cells Trick SARS-CoV-2, Reduce Cytokines In Vitro
Decoy Cells Trick SARS-CoV-2, Reduce Cytokines In Vitro
Genetically engineered cells that overproduce ACE2, the receptor the novel coronavirus uses to enter cells, neutralize infection in vitro and mop up inflammatory cytokines in mice.
Genetically engineered cells that overproduce ACE2, the receptor the novel coronavirus uses to enter cells, neutralize infection in vitro and mop up inflammatory cytokines in mice.
While sick with COVID-19, President Trump is taking an antacid. Doctors have been exploring whether these medicines can treat SARS-CoV-2 infections, and the results are mixed.
Excess of the inflammatory molecule bradykinin may explain the fluid build-up in the lungs of patients with coronavirus infections. Clinical trials of inhibitors are putting this hypothesis to the test.
The results are a proof-of-concept that the novel coronavirus can replicate in neurons, but it’s too soon to say whether this occurs in people with COVID-19.
Eight amino acids are identical to part of the human epithelial sodium channel, leading researchers to suspect the virus might interfere with the channel’s function.
Analyses from single-cell sequencing datasets support the idea that COVID-19 is not just a respiratory disease but an illness that can affect multiple organs.